{{Infobox drug
| drug_name         = 
| INN               = 
| type              = <!-- empty -->
| image             = Ripretinib skeletal.svg
| width             = 
| alt               = 
| caption           = 

<!-- Clinical data -->
| pronounce         = rip re' ti nib
| tradename         = Qinlock
| Drugs.com         = {{drugs.com|ppa|ripretinib}}
| MedlinePlus       = 
| licence_CA        = <!-- Health Canada may use generic or brand name (generic name preferred) -->
| licence_EU        = <!-- EMA uses INN (or special INN_EMA) -->
| DailyMedID        = Ripretinib
| licence_US        = <!-- FDA may use generic or brand name (generic name preferred) -->
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment = 
| pregnancy_US      = <!-- A / B / C / D / X / N -->
| pregnancy_US_comment = 
| pregnancy_category= 禁忌
| dependency_liability = 
| addiction_liability = 
| routes_of_administration = 口服
| class             = 
| ATCvet            = 
| ATC_prefix        = 無
| ATC_suffix        = 
| ATC_supplemental  = 

<!-- Legal status -->
| legal_AU = S4
| legal_AU_comment = 
| legal_BR =  <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR_comment = 
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment = 
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment = 
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment = 
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_UK_comment = 
| legal_US = Rx-only
| legal_US_comment = 
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment = 
| legal_status      = <!-- For countries not listed above -->

<!-- Pharmacokinetic data -->
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| metabolites       = 
| onset             = 
| elimination_half-life = 
| duration_of_action = 
| excretion         = 

<!-- Identifiers -->
| CAS_number_Ref    = 
| CAS_number        = 1442472-39-0
| CAS_supplemental  = 
| PubChem           = 71584930
| PubChemSubstance  = 
| IUPHAR_ligand     = 
| DrugBank_Ref      = 
| DrugBank          = DB14840
| ChemSpiderID_Ref  = 
| ChemSpiderID      = 67886378
| UNII_Ref          = 
| UNII              = 9XW757O13D
| KEGG_Ref          = 
| KEGG              = D11353
| ChEBI_Ref         = 
| ChEBI             = 
| ChEMBL_Ref        = 
| ChEMBL            = 4216467
| NIAID_ChemDB      = 
| PDB_ligand        = 
| synonyms          = DCC-2618

<!-- Chemical and physical data -->
| IUPAC_name        = 3-{4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl}-1-phenylurea
| chemical_formula  = 
| C = 24 | H = 21 | Br = 1 | F = 1 | N = 5 | O = 2
| molecular_weight  = 
| SMILES            = CCN1C(=O)C(=CC2=C1C=C(NC)N=C2)C1=C(Br)C=C(F)C(NC(=O)NC2=CC=CC=C2)=C1
| Jmol              = 
| StdInChI          = 1S/C24H21BrFN5O2/c1-3-31-21-12-22(27-2)28-13-14(21)9-17(23(31)32)16-10-20(19(26)11-18(16)25)30-24(33)29-15-7-5-4-6-8-15/h4-13H,3H2,1-2H3,(H,27,28)(H2,29,30,33)
| StdInChI_comment  = 
| StdInChIKey       = CEFJVGZHQAGLHS-UHFFFAOYSA-N
| density           = 
| density_notes     = 
| melting_point     = 
| melting_high      = 
| melting_notes     = 
| boiling_point     = 
| boiling_notes     = 
| solubility        = 
| sol_units         = 
| specific_rotation = 
}}
'''瑞普替尼'''（Ripretinib）是一種用于治疗晚期[[胃腸道基質腫瘤|胃腸道基質腫瘤]]的药物<ref name="FDA PR">{{Cite press release|website=U.S. [[美国食品药品监督管理局|美国食品药品监督管理局]] (FDA)|accessdate=15 May 2020}}</ref>。該藥物最常见的副作用有[[脫髮|脱发]]、疲倦、恶心、腹痛、[[便秘|便秘]]、[[肌肉痛|肌肉痛]]、[[腹泻|腹泻]]、食欲不振和呕吐。<ref name="FDA PR" /><ref name="FDA snapshot">{{Cite web|title=Drug Trial Snapshot: Qinlock|url=https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trial-snapshot-qinlock|accessdate=2 June 2020|date=15 May 2020|work=U.S. [[美国食品药品监督管理局|美国食品药品监督管理局]] (FDA)|archive-date=2020-12-22|archive-url=https://web.archive.org/web/20201222054407/https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trial-snapshot-qinlock|dead-url=no}} {{PD-notice}}</ref>。  

2020年5月，瑞普替尼在[[美国|美国]]獲得上市許可。<ref name="FDA PR" /><ref>{{Cite press release|website=Deciphera Pharmaceuticals, Inc.|accessdate=15 May 2020}}</ref><ref>{{Cite web|title=Qinlock: FDA-Approved Drugs|url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213973|accessdate=15 May 2020|work=U.S. [[美国食品药品监督管理局|美国食品药品监督管理局]] (FDA)|archive-date=2020-11-27|archive-url=https://web.archive.org/web/20201127063223/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213973|dead-url=no}}</ref><ref name="FDA snapshot" />同年7月28日，瑞普替尼在[[中华人民共和国|中华人民共和国]]投入臨床治療<ref>{{Cite web|title=国内首个“特批带离药物”落地博鳌超级医院|url=http://hi.people.com.cn/n2/2020/0728/c231190-34189760.html|accessdate=|author=人民網|date=|format=|publisher=|language=|archive-date=2020-07-28|archive-url=https://web.archive.org/web/20200728135714/http://hi.people.com.cn/n2/2020/0728/c231190-34189760.html|dead-url=no}}</ref>。    

== 参考资料 ==
{{Reflist}}

== 更多阅读 ==

* {{Cite journal|title=The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis|url=|date=May 2018|journal=Haematologica|issue=5|doi=10.3324/haematol.2017.179895|volume=103|pages=799–809|pmc=5927976|pmid=29439183|display-authors=3}}

== 外部链接 ==

* {{Cite web|title=Ripretinib|url=https://druginfo.nlm.nih.gov/drugportal/name/ripretinib|work=Drug Information Portal|publisher=U.S. National Library of Medicine|access-date=2020-07-28|archive-date=2020-10-21|archive-url=https://web.archive.org/web/20201021020516/https://druginfo.nlm.nih.gov/drugportal/name/ripretinib|dead-url=no}}
* {{Cite web|title=Ripretinib|url=https://www.cancer.gov/publications/dictionaries/cancer-drug/def/kit-pdgfr-inhibitor-dcc-2618|work=National Cancer Institute|access-date=2020-07-28|archive-date=2020-07-28|archive-url=https://web.archive.org/web/20200728113048/https://www.cancer.gov/publications/dictionaries/cancer-drug/def/kit-pdgfr-inhibitor-dcc-2618|dead-url=no}}
* {{ClinicalTrialsGov|NCT03353753|Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)}}
{{細胞外化療藥物}}
[[Category:受体酪氨酸激酶抑制剂|Category:受体酪氨酸激酶抑制剂]]
[[Category:罕用药|Category:罕用药]]
[[Category:癌症治療|Category:癌症治療]]
[[Category:突破療法|Category:突破療法]]
[[Category:抗肿瘤药|Category:抗肿瘤药]]
[[Category:未分配ATC的藥物|Category:未分配ATC的藥物]]
[[Category:带有非标准子页面的Template:drugs.com链接|Category:带有非标准子页面的Template:drugs.com链接]]